|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...2324252627282930313233...3940» |
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - Jul 25, 2013
P3, N=1050, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Not yet recruiting --> Recruiting
- ||| Fanapt LAI (iloperidone depot injectable formulation) / Vanda
Enrollment change: Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients (clinicaltrials.gov) - Jul 24, 2013
P1/2, N=81, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=168 --> 81
- ||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P1 trial: Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia (clinicaltrials.gov) - Jul 24, 2013
P1, N=141, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- New P3 trial: Pyridoxal Kinase Activity in Tardive Dyskinesia (clinicaltrials.gov) - Jul 23, 2013
P3, N=0, Withdrawn, Sponsor: Beersheva Mental Health Center
- Enrollment open, IO biomarker, Immunomodulating: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=80, Recruiting, Sponsor: University of Pittsburgh
N=168 --> 81 Not yet recruiting --> Recruiting
- Enrollment open: Aftercare in the Community Health Center (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=140, Recruiting, Sponsor: Norwegian University of Science and Technology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial withdrawal: Pyridoxal Kinase Activity in Tardive Dyskinesia (clinicaltrials.gov) - Jul 22, 2013
P3, N=0, Withdrawn, Sponsor: Beersheva Mental Health Center
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- clozapine / Generic mfg.
Trial withdrawal: Clozapine IM and Aggression in Schizophrenic Patients (clinicaltrials.gov) - Jul 22, 2013
P3, N=0, Withdrawn, Sponsor: Beersheva Mental Health Center
Not yet recruiting --> Withdrawn Not yet recruiting --> Withdrawn
- clozapine / Generic mfg.
Enrollment change: Clozapine IM and Aggression in Schizophrenic Patients (clinicaltrials.gov) - Jul 22, 2013
P3, N=0, Withdrawn, Sponsor: Beersheva Mental Health Center
Not yet recruiting --> Withdrawn N=20 --> 0
- Trial completion: Transcranial Direct Current Stimulation (tDCS) for Treatment of Negative Syndrome in Patients With Schizophrenia (clinicaltrials.gov) - Jul 18, 2013
P=N/A, N=20, Completed, Sponsor: Ludwig-Maximilians - University of Munich
N=20 --> 0 Recruiting --> Completed
- Enrollment closed: Clinical Validation of the Rating Scale for Psychotic Depression (RAS-PD) (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: S
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Trial completion: Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=129, Completed, Sponsor: University of California, Los Angeles
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Completed
- ||| Enrollment open: Cross-Sectional Iloperidone IVGTT (clinicaltrials.gov) - Jul 16, 2013
P=N/A, N=60, Recruiting, Sponsor: David C. Henderson
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment open: Brexpiprazole in Patients With Schizophrenia (clinicaltrials.gov) - Jul 15, 2013
P3, N=140, Recruiting, Sponsor: H. Lundbeck A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| lenrispodun (ITI-214) - Intra / Cellular Therapies
New P1 trial: Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia (clinicaltrials.gov) - Jul 14, 2013
P1, N=64, Recruiting, Sponsor: Takeda
- Trial completion: Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia (clinicaltrials.gov) - Jul 11, 2013
P4, N=62, Completed, Sponsor: Fundaci
Not yet recruiting --> Recruiting Recruiting --> Completed
- balipodect (TAK-063) / Takeda
Enrollment open: Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults (clinicaltrials.gov) - Jul 9, 2013
P1, N=27, Recruiting, Sponsor: Takeda
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Risperdal Consta (risperidone depot formulation) / J&J
New P4 trial: An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia (clinicaltrials.gov) - Jul 8, 2013
P4, N=640, Terminated, Sponsor: Xian-Janssen Pharmaceutical Ltd.
- |||||||||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
New P3 trial: An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (clinicaltrials.gov) - Jul 8, 2013
P3, N=300, Enrolling by invitation, Sponsor: Alkermes
- Enrollment closed: Supported Employment: Motivational Enhancement for Entry and Outcome (clinicaltrials.gov) - Jul 8, 2013
P2, N=150, Active, not recruiting, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Chantix (varenicline) / Pfizer
Trial completion: SCRP: A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder (clinicaltrials.gov) - Jul 8, 2013
P4, N=295, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment open: The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia. (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=48, Recruiting, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Cognitive Remediation Therapy (CRT) in Adolescents With EOS (clinicaltrials.gov) - Jul 5, 2013
P=N/A, N=50, Completed, Sponsor: Hospital Clinic of Barcelona
Not yet recruiting --> Recruiting Recruiting --> Completed
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment change: Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital (clinicaltrials.gov) - Jul 3, 2013
P4, N=0, Withdrawn, Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting --> Completed N=1000 --> 0
- |||| Trial completion: Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL) (clinicaltrials.gov) - Jul 3, 2013
P4, N=127, Completed, Sponsor: Janssen-Cilag Pty Ltd
N=1000 --> 0 Active, not recruiting --> Completed
- | Risperdal Consta (risperidone depot formulation) / J&J
Trial termination: An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia (clinicaltrials.gov) - Jul 2, 2013
P4, N=640, Terminated, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Terminated; The study was terminated because of high dropout rate.
- Enrollment change: Effectiveness of Cognitive Remediation in a Supported Education Setting (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=37, Completed, Sponsor: Centre for Addiction and Mental Health
Not yet recruiting --> Terminated; The study was terminated because of high dropout rate. N=64 --> 37
- | balipodect (TAK-063) / Takeda
New P1 trial: Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults (clinicaltrials.gov) - Jul 2, 2013
P1, N=27, Recruiting, Sponsor: Takeda
- osoresnontrine (BI 409306) / Boehringer Ingelheim
New P1 trial: Safety and Tolerability of BI 409306 in Patients With Schizophrenia (clinicaltrials.gov) - Jul 2, 2013
P1, N=40, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
- Trial completion: Effectiveness of Cognitive Remediation in a Supported Education Setting (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=37, Completed, Sponsor: Centre for Addiction and Mental Health
N=64 --> 37 Recruiting --> Completed
- Enrollment change: The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia (clinicaltrials.gov) - Jun 30, 2013
P=N/A, N=2025, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed N=1680 --> 2025
- Enrollment change: CAT-Denmark: Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia (clinicaltrials.gov) - Jun 26, 2013
P=N/A, N=65, Completed, Sponsor: University of Southern Denmark
N=1680 --> 2025 N=164 --> 65
- Enrollment closed: Cognitive Behaviour Therapy and Cognitive Training in Work Rehabilitation for Persons With Severe Mental Illness (clinicaltrials.gov) - Jun 26, 2013
P=N/A, N=240, Active, not recruiting, Sponsor: Oslo University Hospital
N=164 --> 65 Recruiting --> Active, not recruiting
- Trial completion: CAT-Denmark: Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia (clinicaltrials.gov) - Jun 26, 2013
P=N/A, N=65, Completed, Sponsor: University of Southern Denmark
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia (clinicaltrials.gov) - Jun 26, 2013
P3, N=546, Completed, Sponsor: Johnson & Johnson Pte Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| risperidone / Generic mfg.
New P3 trial: Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Jun 25, 2013
P3, N=347, Completed, Sponsor: Janssen-Cilag S.p.A.
- | bitopertin (DISC-1459) / Disc Medicine
Enrollment closed: A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) (clinicaltrials.gov) - Jun 24, 2013
P3, N=629, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| risperidone / Generic mfg.
Trial completion: Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Jun 24, 2013
P3, N=347, Completed, Sponsor: Janssen-Cilag S.p.A.
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- acetylcysteine solution / Generic mfg.
New P1 trial: NACSZ: N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia (clinicaltrials.gov) - Jun 20, 2013
P1, N=24, Active, not recruiting, Sponsor: VA Greater Los Angeles Healthcare System
- ||| Trial completion: RECONNECT-S: Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia (clinicaltrials.gov) - Jun 18, 2013
P=N/A, N=1076, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Completed Recruiting --> Completed
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Trial completion: Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients (clinicaltrials.gov) - Jun 17, 2013
P4, N=67, Completed, Sponsor: Qualissima
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Comparison of Video Consent Versus Routine Consent for Participation in Research Studies (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=382, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed Active, not recruiting --> Completed
- ||| balipodect (TAK-063) / Takeda
New P1 trial: Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants (clinicaltrials.gov) - Jun 16, 2013
P1, N=60, Recruiting, Sponsor: Takeda
- Enrollment open: Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis (clinicaltrials.gov) - Jun 15, 2013
P=N/A, N=120, Recruiting, Sponsor: Pakistan Association of Cognitive Therapists
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | AMG 747 / Amgen
Trial termination: 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165) (clinicaltrials.gov) - Jun 13, 2013
P2, N=111, Terminated, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Terminated; Toxic Epidermal Necrolysis
- | AMG 747 / Amgen
Trial termination: 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (clinicaltrials.gov) - Jun 13, 2013
P2, N=121, Terminated, Sponsor: Amgen
Recruiting --> Terminated; Toxic Epidermal Necrolysis Recruiting --> Terminated; Toxic Epidermal Necrolysis
- AMG 747 / Amgen
Enrollment change: 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165) (clinicaltrials.gov) - Jun 13, 2013
P2, N=111, Terminated, Sponsor: Amgen
Recruiting --> Terminated; Toxic Epidermal Necrolysis N=270 --> 111
- AMG 747 / Amgen
Enrollment change: 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (clinicaltrials.gov) - Jun 13, 2013
P2, N=121, Terminated, Sponsor: Amgen
N=270 --> 111 N=270 --> 121
- Clinical data: Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis (clinicaltrials.gov) - Jun 13, 2013
P=N/A, N=264, Recruiting, Sponsor: North Shore Long Island Jewish Health System
- Enrollment change: RQP-MH: The Right Question Project-Mental Health: An Intervention to Increase Engagement and Retention in Mental Health Care (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=724, Completed, Sponsor: Cambridge Health Alliance
N=270 --> 121 N=450 --> 724